QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
Free Trial
NYSE:MNK

Mallinckrodt (MNK) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free MNK Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.07
▼
$0.13
50-Day Range
$0.14
▼
$0.75
52-Week Range
$0.75
▼
$6.42
Volume
39,227 shs
Average Volume
2.62 million shs
Market Capitalization
$1.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial Media
MNK stock logo

About Mallinckrodt Stock (NYSE:MNK)

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

MNK Stock News Headlines

April 14, 2024 | finanznachrichten.de
Mallinckrodt plc: Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
March 26, 2024 | finance.yahoo.com
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
April 16, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
March 4, 2024 | finanznachrichten.de
Mallinckrodt plc: Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands
March 4, 2024 | finance.yahoo.com
Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty Brands
March 1, 2024 | markets.businessinsider.com
Mallinckrodt Says FDA Grants SNDA For Acthar Gel Single-Dose Pre-Filled SelfJect Injector
February 24, 2024 | benzinga.com
Mallinckrodt Stock (OTC:MCKPF) Dividends: History, Yield and Dates
February 21, 2024 | finanznachrichten.de
Mallinckrodt plc: Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS CELLEX Photopheresis System Treatment at the 2024 Tandem Meetings
April 16, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
February 3, 2024 | msn.com
Mallinckrodt Announces Executive Appointments and Incentive Plans
January 31, 2024 | morningstar.com
Mallinckrodt PLC Ordinary Shares - New
January 9, 2024 | msn.com
Mallinckrodt to discontinue StrataGraft due to slow uptake
December 27, 2023 | finance.yahoo.com
Mallinckrodt Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index
December 7, 2023 | sg.finance.yahoo.com
Mallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® (nitric oxide) Mini-Cylinder
December 1, 2023 | msn.com
Mallinckrodt Avoids $40 Million SEC Fine in Medicaid Overcharge Case
November 16, 2023 | finance.yahoo.com
Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results
November 15, 2023 | msn.com
Mallinckrodt emerges from bankruptcy
November 14, 2023 | finance.yahoo.com
Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11
October 11, 2023 | msn.com
Mallinckrodt sees emerging from Chapter 11 by end of year
October 11, 2023 | msn.com
Mallinckrodt Bankruptcy Plan Gets Approval, Will Wipe Out $1 Billion in Opioid Payments
October 11, 2023 | finance.yahoo.com
Mallinckrodt Approved to End Bankruptcy, Reduce Opioid Payments
October 10, 2023 | reuters.com
Mallinckrodt gets court approval for restructuring, $1 bln cut to opioid settlement
October 10, 2023 | finance.yahoo.com
Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan
September 20, 2023 | msn.com
Firm Retention Summary: Mallinckrodt
September 20, 2023 | msn.com
Drug giant Mallinckrodt enters second Irish Examinership
September 19, 2023 | msn.com
Bankrupt Drugmaker Mallinckrodt Considers Sale of Opioid Business
September 1, 2023 | benzinga.com
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)
See More Headlines
Receive MNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/04/2020
Today
4/16/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:MNK
CUSIP
N/A
CIK
1567892
Web
www.mallinckrodt.com
Phone
(531) 696-0000
Fax
N/A
Employees
2,700
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($116.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
-82.59%
Pretax Margin
N/A
Return on Equity
20.32%
Return on Assets
2.49%

Debt

Debt-to-Equity Ratio
1.18
Current Ratio
0.57
Quick Ratio
0.31

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$47.48 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
13,170,000
Free Float
13,131,000
Market Cap
$1.58 million
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover
The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mark C. Trudeau
    President, Chief Executive Officer & Director
  • Bryan M. Reasons
    Chief Financial Officer & Executive Vice President
  • Steven Joseph Romano
    Chief Scientific Officer & Executive VP
  • Babatunde Adekunle Otulana
    Chief Medical Officer & Senior Vice President
  • Michele Robertson
    Chief Compliance Officer & Senior Vice President

Key Competitors

View All Competitors

MNK Stock Analysis - Frequently Asked Questions

How were Mallinckrodt's earnings last quarter?

Mallinckrodt plc (NYSE:MNK) issued its quarterly earnings results on Tuesday, August, 4th. The company reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.55. The business earned $700.90 million during the quarter, compared to the consensus estimate of $630.19 million. Mallinckrodt had a positive trailing twelve-month return on equity of 20.32% and a negative net margin of 82.59%. The company's quarterly revenue was down 14.9% on a year-over-year basis. During the same quarter last year, the company earned $2.53 earnings per share.
Read the conference call transcript.

What other stocks do shareholders of Mallinckrodt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), Advanced Micro Devices (AMD).

This page (NYSE:MNK) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
The Greatest Bull Market in Crypto History…
Weiss Ratings